Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 in advanced malignant solid tumors
NCT05773937Phase 1Recruiting
- Sponsor
- Mabwell
- Start
- Jun 2022
- Primary completion
- Dec 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bulumtatug fuvedotin in malignant solid tumor and urothelial carcinoma (UC), sponsored by Mabwell. Primary endpoint: Incidence of adverse events. Started Jun 2022; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
malignant solid tumorurothelial carcinoma (UC)
Beyond the preview
Go deeper on NCT05773937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05773937.